Market Cap 5.40B
Revenue (ttm) 290.52M
Net Income (ttm) 89.16M
EPS (ttm) N/A
PE Ratio 37.89
Forward PE 37.80
Profit Margin 30.69%
Debt to Equity Ratio 0.00
Volume 140,200
Avg Vol 303,160
Day's Range N/A - N/A
Shares Out 28.94M
Stochastic %K 31%
Beta 0.64
Analysts Strong Sell
Price Target $218.10

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
ZManicItalian
ZManicItalian Oct. 22 at 10:31 PM
$KRYS Japan commercial launch is a go 💪 https://www.linkedin.com/posts/krystal-biotech-inc_investor-news-krystal-biotech-japan-announced-activity-7386793424479477760-6gzK?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAGBoSQBdIRLFO0gpLrUSXR2U8D-Tm6shcE&utm_campaign=copy_link
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 21 at 11:54 AM
$KRYS another one in the same sector, with much more promising-looking chart. $BEAM had a monster 17.86% day.
0 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 12:01 PM
$KRYS https://anachart.com/wp-content/uploads/ana_temp/1760702500_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 11:02 AM
B of A Securities updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 182 → 255.
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:12 PM
H.C. Wainwright reiterated $ABEO Buy/$20 $KRYS HCW said: Last week, Abeona Therapeutics announced the activation of Children's Hospital Colorado as the newest qualified treatment center (QTC) for Abeona's marketed product ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO—one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB) and a member of the EB Clinical Research Consortium—has completed the applicable QTC start-up activities, enabling the initiation of patient identification for scheduling of ZEVASKYN treatment. In our view, the establishment of another QTC demonstrates Abeona's continued execution with respect to the rollout of ZEVASKYN. We reiterate our Buy rating and 12-month price target of $20.
0 · Reply
Ortho91
Ortho91 Oct. 11 at 2:03 AM
$KRYS shorts are playing with fire now.
0 · Reply
Fugazi_
Fugazi_ Oct. 7 at 6:55 AM
$KRYS Who keeps trading the 220 call option?
1 · Reply
TapeBenji
TapeBenji Oct. 5 at 9:31 AM
$KRYS Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
Ortho91
Ortho91 Oct. 4 at 1:50 AM
$KRYS looks great from buying more at lows. Now we are 183. Going to 225 by December or more
0 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
1 · Reply
Latest News on KRYS
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:42 PM EDT - 2 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:43 PM EDT - 6 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 6 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences


Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 7 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer


Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:43 AM EST - 8 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript


Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 27, 2024, 8:30 AM EST - 10 months ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy


Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 11 months ago

Krystal Biotech to Present at Upcoming Investor Conferences


Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:47 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript


ZManicItalian
ZManicItalian Oct. 22 at 10:31 PM
$KRYS Japan commercial launch is a go 💪 https://www.linkedin.com/posts/krystal-biotech-inc_investor-news-krystal-biotech-japan-announced-activity-7386793424479477760-6gzK?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAGBoSQBdIRLFO0gpLrUSXR2U8D-Tm6shcE&utm_campaign=copy_link
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 21 at 11:54 AM
$KRYS another one in the same sector, with much more promising-looking chart. $BEAM had a monster 17.86% day.
0 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 12:01 PM
$KRYS https://anachart.com/wp-content/uploads/ana_temp/1760702500_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 11:02 AM
B of A Securities updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 182 → 255.
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:12 PM
H.C. Wainwright reiterated $ABEO Buy/$20 $KRYS HCW said: Last week, Abeona Therapeutics announced the activation of Children's Hospital Colorado as the newest qualified treatment center (QTC) for Abeona's marketed product ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO—one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB) and a member of the EB Clinical Research Consortium—has completed the applicable QTC start-up activities, enabling the initiation of patient identification for scheduling of ZEVASKYN treatment. In our view, the establishment of another QTC demonstrates Abeona's continued execution with respect to the rollout of ZEVASKYN. We reiterate our Buy rating and 12-month price target of $20.
0 · Reply
Ortho91
Ortho91 Oct. 11 at 2:03 AM
$KRYS shorts are playing with fire now.
0 · Reply
Fugazi_
Fugazi_ Oct. 7 at 6:55 AM
$KRYS Who keeps trading the 220 call option?
1 · Reply
TapeBenji
TapeBenji Oct. 5 at 9:31 AM
$KRYS Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
Ortho91
Ortho91 Oct. 4 at 1:50 AM
$KRYS looks great from buying more at lows. Now we are 183. Going to 225 by December or more
0 · Reply
VAK7
VAK7 Oct. 1 at 8:41 PM
1 · Reply
MaverikIT
MaverikIT Sep. 29 at 5:36 PM
0 · Reply
AJALMOSAWY
AJALMOSAWY Sep. 29 at 3:27 PM
0 · Reply
projectmechadoge
projectmechadoge Sep. 26 at 4:39 AM
$KRYS grok just told me to buy this , no position
0 · Reply
Fugazi_
Fugazi_ Sep. 24 at 9:25 PM
$KRYS Never seen 1.8k volume, and then the next day it dissapears, no OI or anything. Very odd
0 · Reply
ZManicItalian
ZManicItalian Sep. 22 at 2:05 PM
$KRYS going $200+ in 2026 if not by the end of this year
0 · Reply
aaxaa
aaxaa Sep. 19 at 2:29 PM
0 · Reply
enriquesaaa
enriquesaaa Sep. 18 at 7:53 PM
$KRYS squeeze baby squeeze
0 · Reply
enriquesaaa
enriquesaaa Sep. 18 at 7:53 PM
$KRYS My gosh, sitting at 160$ 🤩🤩🤩
0 · Reply
ZManicItalian
ZManicItalian Sep. 18 at 4:29 PM
$KRYS bust through $160. Do that damn thing!
0 · Reply
alexpitti
alexpitti Sep. 16 at 11:42 PM
$KRYS investors can scream about the competitive landscape and act like they are right about what patients will choose because $ABEO has fallen recently, but of course competition has nothing to do with manufacturing. Abeona needs to actually produce the sheets and put them on patients before we see how the landscape develops. The demand is there, hospitals want it, and insurers are reimbursing it. The question right now is manufacturing and the results over time of the product.
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 5:23 PM
$KRYS just got a major catalyst 🚀 FDA expanded Vyjuvek’s label to cover DEB patients from birth, plus at-home use flexibility — a big win fueling today’s rally. Full breakdown of the move here 👉 https://www.zacks.com/stock/news/2752364/krystal-biotech-stock-up-on-fda-nod-to-vyjuvek-label-update?cid=sm-stocktwits-2-2752364-teaser-12720&ADID=SYND_STOCKTWITS_TWEET_2_2752364_TEASER_12720
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 4:23 PM
$KRYS jumps 8.4% on FDA label update for Vyjuvek 🚀 This allows DEB treatment from birth and at-home administration, increasing convenience and potential future sales. With recent approvals in Europe and Japan, Vyjuvek is set for expansion with planned launches in Germany and France in 2025. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2752364/krystal-biotech-stock-up-on-fda-nod-to-vyjuvek-label-update?cid=sm-stocktwits-2-2752364-body-12699&ADID=SYND_STOCKTWITS_TWEET_2_2752364_BODY_12699
0 · Reply